Six.02 snaps up Kempbio

Six.02 Bioservices announces first acquisition, relaunches leading protein expression provider Kempbio as Kemp Proteins

Register for free to listen to this article
Listen with Speechify
FREDERICK, Md.—Six.02 Bioservices has announced the acquisition of Kempbio, a leading provider of gene-to-protein bioservices for innovators developing human and veterinary biopharmaceuticals, vaccines, and diagnostics across the life sciences. The terms of the transaction have not been disclosed.
Kempbio has been re-launched as Kemp Proteins in connection with the acquisition. According to a press release, the name change “reflects the company’s evolved position from its founding to its current status as a premier provider of customized protein bioservices with a reputation for expertise in solving unique protein-related challenges.” Kemp Proteins is a provider of gene-to-protein services, known for its strength in solving the most difficult protein-expression challenges. For more than 20 years, the company’s experienced team of protein problem-solvers has generated all protein types for protein-focused R&D.
Chris Kemp, Ph.D., founder and president of Kempbio, has retained a partial ownership of Kemp Proteins and will serve as chief scientific officer. Michael Keefe, a partner at Six.02 Bioservices, will serve as chief executive officer of Kemp Proteins.
“We are thrilled to announce Kemp Proteins as the first member of the Six.02 family of companies,” said Keefe. “Kempbio’s leadership is built on a long track record of scientific and technical excellence and achievement—in particular, the team’s exceptional ability to solve the most intractable protein expression challenges.”
According to Six.02 Bioservices, the company is focused on acquiring and managing specialized bioservices companies that are well-positioned for growth, based on their ability to deliver best-in-class services that optimize productivity and mitigate risk for protein-based innovators. Six.02 is looking for companies in the human and veterinary biopharmaceutical, vaccine and diagnostics sectors.
“We’re very excited to join the Six.02 Bioservices family of companies and begin work as Kemp Proteins,” Kemp noted. “Six.02’s commitment to outstanding quality, expertise, and customer service aligns directly with our commitment to provide best-in-class services that assist our clients in their protein-based research and development. We look forward to leveraging our established industry position with Six.02’s expertise in marketing, project management, and quality management systems.”
Six.02 also says they plan to invest in expanded laboratory space and additional cutting-edge equipment and technologies to enhance Kemp Proteins’ portfolio of service options and to meet the growing market demand for more efficient, flexible and reliable outsourcing services tackling the complex challenges of protein-based research and product development. Kemp Proteins will be positioned as a quality-focused bioservices company with the implementation of an ISO-compliant quality management system.
“Over the past 20 years, the talented Kemp team has elevated this company to distinction based on its ability to help life sciences companies of all sizes solve the most unique and complex protein production challenges. We have chosen to retain the ‘Kemp’ name and iconic green as a signal that our customers will still be working with the same great team and expertise they’ve come to rely on over the years. We look forward to working together to expand the company’s portfolio of services and increase its capabilities in support of innovators tackling the complex challenges of protein-based research and product development across the life sciences,” added Keefe.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue